#Germany #Frankfurt #Kexing Biopharm #Global Strategies #CPHI Frankfurt

Kexing Biopharm Demonstrates its Global Strategy at CPHI Frankfurt 2025

Kexing Biopharm, a multinational biopharmaceutical company, showcased its global strategy and partnership opportunities at CPHI Frankfurt 2025, held from October 28 to 30. This exhibition is one of the most influential events in the pharmaceutical sector, enabling companies to connect with global partners and stakeholders.

During the three-day event, Kexing Biopharm's international team participated in numerous productive meetings with representatives from various countries in the industry. Key topics discussed included product registration, market access, and local collaboration strategies. Kexing presented its comprehensive pharmaceutical capabilities, spanning from innovative active pharmaceutical ingredients (APIs) to finished dosage forms, all supported by quality systems that comply with international regulations.

The CPHI Frankfurt is not merely a platform for showcasing products and services; it serves as a vital gateway for sharing information and integrating industry resources. Kexing’s team actively visited competitor booths, scheduled meetings with clients, and exchanged insights with industry partners regarding global pharmaceutical trends and overseas market dynamics. This initiative enabled Kexing to gain invaluable experience, optimizing its foreign expansion strategy while identifying potential clients.

In recent years, Kexing Biopharm has vigorously promoted its “Global Selection + Global Coverage” strategy, identifying and introducing high-quality products in oncology, autoimmune diseases, metabolism, and specialized therapeutic areas. With this platform-based model of internationalization, Kexing aims to accelerate the market entry of high-quality Chinese pharmaceuticals worldwide.

Kexing is committed to solidifying its global market presence through open collaboration, professional operations, and a patient-centered approach, intending to deliver accessible and high-quality health solutions to patients across more regions.

As a multinational corporation traded under the stock symbol 688136.SH, Kexing Biopharm is dedicated to research and development, manufacturing, and selling innovative drugs across various modalities, including recombinant proteins, antibodies, and cell/gene therapies.

By creating advanced technological platforms to foster the development of new targeted therapies and drug delivery systems, Kexing aims to address unmet clinical needs in oncology and autoimmune and antiviral treatments, significantly impacting patients’ daily lives.

Aligned with its platform development model driven by two engines—innovation and internationalization—Kexing strives to emerge as a global leader in high-quality biopharmaceutical products, enhancing patient health worldwide.

As the pharmaceutical industry consistently evolves, Kexing Biopharm's proactive stance and commitment to excellence position it favorably for future partnerships and collaborations that could lead to exciting advancements in global health.